<DOC>
	<DOCNO>NCT02332720</DOCNO>
	<brief_summary>This randomize , three-part , parallel-group , open-label trial grazoprevir ( MK-5172 ) ( 100 mg ) MK-3682 ( 300 mg 450 mg ) either elbasvir ( MK-8742 ) ( 50 mg ) ruzasvir ( MK-8408 ) ( 60 mg ) , without ribavirin ( RBV ) , treatment-naive ( TN ) treatment-experienced ( TE ) cirrhotic ( C ) non-cirrhotic ( NC ) participant infect hepatitis C virus ( HCV ) genotype ( GT ) 3 , GT4 , GT5 , GT6 . Part A consist 4 arm evaluate safety dose combination . In Part B , participant take 2 MK-3682B fix dose combination ( FDC ) tablet daily ( q.d . ) mouth , without twice-daily ( b.i.d . ) RBV ( 200 mg capsule ; weight-based dosing ) . Participants relapse follow completion therapy Part A offer option retreatment 16 week MK-3682B RBV Part C ( data obtain Part C use analysis outcome measure ) .</brief_summary>
	<brief_title>Efficacy Safety Grazoprevir ( MK-5172 ) MK-3682 With Elbasvir ( MK-8742 ) Ruzasvir ( MK-8408 ) Chronic Hepatitis C Virus ( HCV ) Genotype ( GT ) 3 , GT4 , GT5 , GT6 Infection ( MK-3682-012 )</brief_title>
	<detailed_description>In Part A , study therapy administer separate product , take q.d . mouth . In Part B Part C , participant take 2 MK-3682B FDC tablet q.d . mouth ; MK-3682B FDC tablet contain grazoprevir 50 mg + MK-3682 225 mg + ruzasvir 30 mg .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Has document chronic HCV GT3 , GT4 , GT5 , GT6 evidence nontypeable mixed GT infection Is otherwise healthy determine medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory measurement perform time screening Has cirrhosis liver ( Part B ) noncirrhotic ( Part A B ) Is HCV treatmentnaïve experience virologic failure complete prior Pegylated Interferon/Ribavirin ( PegIFN/RBV ) regimen Is non childbearing potential agrees avoid become pregnant impregnating partner begin least 2 week prior administration initial dose study drug 14 day last dose study drug take RBV , 6 month last dose study drug take RBV ( longer dictate local regulation ) . If abstinent heterosexual activity , participant Part A must use 2 acceptable form barrier contraception whereas participant Parts B C must use 2 acceptable form contraception may include oral contraceptive Part B : If coinfected human immunodeficiency virus ( HIV ) currently antiretroviral therapy ( ART ) plan initiate ART treatment participate study OR wellcontrolled HIV ART . Has least 1 viable antiretroviral regimen alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance . Parts A , B , C ( unless otherwise specify ) : Has evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease . If cirrhotic ( Part B ) , ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 5 . Is coinfected hepatitis B virus ( Parts A , B , C ) coinfected HIV ( Part A ; HIV coinfected participant eligible Parts B C ) . If coinfected HIV , history opportunistic infection precede 6 month prior screen . Has history malignancy ≤5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspected malignancy . Has cirrhosis liver image within 6 month Day 1 show evidence hepatocellular carcinoma ( HCC ) evaluation HCC . Has clinicallyrelevant drug alcohol abuse within 12 month screen . Is female pregnant breastfeeding , expect conceive donate egg least 2 week prior Day 1 90 day last dose study medication , longer dictate local regulation OR male subject expect donate sperm least 2 week prior day 1 90 day last dose study medication . Has follow condition : Organ transplant ( include hematopoietic stem cell transplant ) cornea hair . Poor venous access precludes routine peripheral blood sampling require trial . History gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) . Current history clinically significant cardiac abnormalities/dysfunction , include limited : angina , congestive heart failure , myocardial infarction , pulmonary hypertension , complex congenital heart disease , cardiomyopathy , significant arrhythmia , uncontrolled hypertension , history use antianginal antiarrythmic agent cardiac condition , prolong ECG QTc interval ( &gt; 470 m male &gt; 480 m female either Bazett Fridericia formula ) screen visit , personal family history Torsade de pointes . Chronic pulmonary disease , include limited : clinically significant chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis , sarcoidosis . Central nervous system ( CNS ) trauma require intubation , intracranial pressure monitoring , brain meningeal skull surgery , result seizure , coma , permanent neurologic deficit , abnormal brain imaging , cerebral spinal fluid ( CSF ) leak . Prior brain hemorrhage and/or intracranial aneurysm ( whether adequately repair ) . Current history seizure disorder unless seizure &gt; 10 year ago , single isolated event , history current use antiseizure medication prescribe , normal neurological examination document trial file within 6 month Day 1 . Has history stroke transient ischemic attack . Has history medical/surgical condition result hospitalization within 3 month prior enrollment , minor elective procedure . Has medical/surgical condition may result need hospitalization period study . Has medical condition requiring , likely require , chronic systemic administration corticosteroid , tumor necrosis factor ( TNF ) antagonists , immunosuppressant drug course trial . Has condition , prestudy laboratory ECG abnormality history illness , , opinion investigator , might confound result study pose additional risk administer study drug subject . Has lifethreatening serious adverse event ( SAE ) screen period . Has evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , hemochromatosis , Wilson 's disease , α1antitrypsin deficiency , alcoholic liver disease autoimmune hepatitis Parts B C : male whose female partner ( ) is/are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>